Chip
Scan genome-wide with CpG island and promoter tiling microarrays. Focus in on regions of interest with custom microarrays. Identify and profile methylation with Agilent’s DNA Methylation Application.
Epigenetic methylation events are heritable modifications that regulate gene expression without altering the DNA sequence itself. They serve as regulatory mechanisms for a wide range of biological processes and genetic diseases, and irregular methylation patterns have been correlated with certain cancers. Methylation microarrays facilitate global investigation of regulatory events, in vivo, without the limitations of gene-specific analyses or the hands-on time required by chromatography-based methods. Agilent’s CpG and promoter microarrays enable genome-wide scanning of methylation events, while our custom arrays allow you to target specific regions for finer resolution evaluation. Through SurePrint inkjet technology, unique probe design algorithms, and validated protocols, Agilent’s DNA Methylation Solution empowers you with the flexibility, sensitivity, and specificity to identify the methylation events that matter most to you.
- Engineered for flexibility – Agilent’s SurePrint inkjet technology prints oligos on demand, enabling you to define content for any tiling density, promoter region, or organism of interest.
- Focused on sensitivity – Agilent’s 60-mer oligonucleotides combined with unique probe design algorithms deliver higher sensitivity, accuracy, and reproducibility for detecting methylation events.
- Designed for specificity – Agilent’s targeted probes and validated mDIP protocols ensure identification of the regions that matter most to your research, while producing fewer false positives.
Methylation, mutation, and cancer: new insights into the transcriptome
A review of Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer
The loss of proper gene function during human cancer progression has been established to occur through both genetic and epigenetic mechanisms. Schuebel and colleagues (2007) developed a transcriptome-wide approach to identify genes affected by promoter CpG island DNA hypermethylation and transcriptional silencing in colorectal cancer. The researchers stratified genes according to altered signal intensity on Agilent’s 44K human microarrays to compare wild type (WT) and isogenic knockout counterparts for DNA methyltransferase 1 or 3b and identify global hypermethylation-dependent gene expression changes in human colorectal cancer cells (CRC). Agilent’s microarrays helped the group readily identify candidate cancer genes in single tumors with a high efficiency of validation, which can then be compared to mutated genes previously identified for CRC to establish key relationships between the altered tumor genome and hypermethylome. The research presented in this paper contributes to understanding the molecular pathways driving tumorigenesis; provides useful new DNA hypermethylation biomarkers to monitor cancer risk assessment, early diagnosis, and prognosis; and permits better monitoring of gene expression during cancer prevention and/or therapeutic strategies.
More
Elucidating the Functional Significance of Methylation Regulatory Events
A review of Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2.
More
CpG Island Microarrays Identify Gene Methylation in Lung Cancer
A review of Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay.
More
Uncovering the Mechanisms of Gene Regulation using Microarrays
A review of Detection and discovery of RNA modifications using microarrays.
More